期刊文献+

RP-HPLC测定阿托伐他汀钙分散片的含量 被引量:8

Determination of atorvastatin calcium in dispersible tablets by RP-HPLC
原文传递
导出
摘要 目的:建立高效液相色谱法测定阿托伐他汀钙分散片的含量。方法:采用Lichrospher C18(250mm×4.6 mm,5μm)色谱柱,流动相为乙腈-0.02 mol.L-1KH2PO4(60∶40,用磷酸调pH至4.0),检测波长246 nm,流速1.0 mL.m in-1,进样体积20μL。结果:阿托伐他汀钙在1-400μg.mL-1的范围内呈良好的线性关系,相关系数为r=0.999 9;回收率100.17%,RSD为0.84%。结论:本方法简便、准确、专属性强,可用于阿托伐他汀钙分散片的含量的测定。 Objective: To develop a simple,rapid,precise and accurate isocratic reversed-phase HPLC method for analysis of atorvastatin in dispersible tablets.Methods: Separation was achieved on a Lichrospher C18(250 mm×4.6 mm,5 μm) column using a mobile phase consisting of acetonitrile-0.02 mol·L-1 KH2PO4 buffer(60∶40,pH was adjusted to 4.0 with phosphoric acid) at a flow rate of 1.0 mL·min-1 and UV detection at 246 nm.Results: A good linearity was obtained in the range of 1~400 μg·mL-1(r=0.999 9).The average recovery was 100.17%,RSD=0.84%.Conclusion: This method has shown good resolution for atorvastatin,main impurities,degradation products and formulation excipients of dispersible tablets.Degradation products do not interfere with the detection of atorvastatin and the assay can thus be considered stability-indicating.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第4期382-384,共3页 Chinese Journal of New Drugs
关键词 阿托伐他汀分散片 高效液相色谱法 含量测定 atorvastatin calcium dispersible tablets HPLC determination
  • 相关文献

参考文献7

  • 1LEA AP,MCTAVISH D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidemias [J]. Drugs, 1997,53(5):828-847.
  • 2蒲强红,姜成,吕秋菊.紫外可见分光光度法测定阿托伐他汀钙片含量[J].安徽医药,2009,13(3):273-274. 被引量:13
  • 3BAHRAMI G,MOHAMMADI B,MIRZAEEI S,et al. Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection[J]. J Chromatogr B,2005,826(2) :41 -45.
  • 4封宇飞,刘志鹤,吴学军,姜文清,邹定.毛细管区带电泳法测定阿托伐他汀钙片的含量及降解产物[J].中国药学杂志,2003,38(6):456-458. 被引量:17
  • 5KADAV AA,VORA DN. Stability indicating UPLC method for simuhaneous determination of atorvastatin, fenofibrate and their degradation products in tablets[ J]. J Pharm Biomed Anal,2008, 48(! ) :120 - 126.
  • 6MAZUREK S,SZOSTAK R. Quantification of atorvastatin calcium in tablets by FT-Raman spectroscopy[J]. J Pharm Biorned Anal, 2009,49( 1 ) :168 - 172.
  • 7沈海蓉,李中东,施孝金,钟明康.阿托伐他汀钙自微乳的HPLC测定[J].中国医药工业杂志,2005,36(4):223-225. 被引量:7

二级参考文献13

  • 1Kadav AA,Vora DN. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets[ J ]. J Pharm Biomed Anal ,2008,48 (1):120- 6.
  • 2Mohammadi A, Rezanour N, Ansari Dogaheh M, et al. A stability - indicating high performance liquid chromatographic ( HPLC ) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets[ J]. J Chromatogr B Analyt Technol Biomed Life Sci. 2007,846( 1 -2) :215 -21.
  • 3Joseph L, George M, Rao B VR. Simultaneous estimation of atorvastatin and ramipril byRP-HPLC and spectroscopy [ J ]. Pak J Pharm Sci,2008,21 (3) :282 -4.
  • 4Chaudhari BG, Patel NM, Shah PB. Stability indicating RP-HPLC method for simuhaneousdetermination of atorvastatin and amlodipine from their combination durg products [ J ]. ChemPharm Bull ( Tokyo) ,2007,55(2) :241 -6.
  • 5Stanisz B, Kania L. Validation of HPLC method for determination of atorvastatin in tablets andfor monitoring stability in solid phase[ J]. Acta Pol Pharm,2006,63(6) :471 -6.
  • 6Bullen WW,Miller RA,Hayes RN, et al. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin,and para-hydroxy atorvastatin in human,dog,and rat plasma[J].J Am Soc Mass Spectrom, 1999,10(1 ) : 55.
  • 7Jemal M,Ouyang Z,Chen BC, et al. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom, 1999,13(11) : 1003.
  • 8Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias [J]. Drugs, 1997, 53 (5): 828-847.
  • 9Erturk S, Sevinc Aktas E, Ersoy L, et al. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets [J]. J Pharm Biomed Anal, 2003, 33 (5): 1017-1023.
  • 10Jemal M, Ouyang Z, Chen BC, et al. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry [J]. Rapid Commun Mass Spectrom, 1999, 13 (11): 1003-1015.

共引文献26

同被引文献45

引证文献8

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部